Article - 09/05/2013 Immunoproteasome Drug Targeting: Immunoproteasome inhibitors allow control of autoimmune diseases Marcus Groettrup is the chair of immunology at the University of Konstanz and has been active in the field of immunology for many years. In 2009 Groettrup made a discovery that led to him setting up a company. His analysis of immunoproteasomes whose main function is to degrade unneeded or damaged proteins showed that these protein complexes also play a major role in the development of autoimmune diseases. Based on this knowledge Groettrup…https://www.gesundheitsindustrie-bw.de/en/article/news/immunoproteasome-drug-targeting-immunoproteasome-inhibitors-allow-control-of-autoimmune-diseases
Article - 25/02/2013 Molecular monitoring of premature infants Premature births are not uncommon in Germany where around seven percent of newborns are born before week 37 of pregnancy. The WHO estimates that the numbers of preterm births are growing due to the increasing age of mothers. Doctors caring for the tiny patients are faced with a dilemma because regular blood samples required for the clinical monitoring of important blood parameters cannot be taken due to the infants low body volume.https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-monitoring-of-premature-infants
Article - 04/02/2013 G protein-coupled receptors and their importance for research and development Brian Kobilka and Robert Lefkowitz were awarded the 2012 Nobel Prize in Chemistry for their groundbreaking discoveries of the inner workings of G protein-coupled receptors (GPCRs). These transmembrane receptors play a key role in the processing of odours and the recognition of hormones. The work of the two American scientists has had an impact on many researchers around the world. In the following interview, Professor Dr. Daniel Legler, head of…https://www.gesundheitsindustrie-bw.de/en/article/news/g-protein-coupled-receptors-and-their-importance-for-research-and-development
Article - 07/01/2013 Small RNAs and immunological reactions Patients with common variable immunodeficiency CVID lack antibodies that would protect them against infections. Only a handful of patients develop the disease because of a single defect in any of the genes involved in CVID pathogenesis. A group of researchers led by Dr. Ulrich Salzer at the Centre for Chronic Immunodeficiency CCI at the University of Freiburg Medical Centre investigates how small RNA molecules control B-lymphocyte development as…https://www.gesundheitsindustrie-bw.de/en/article/news/small-rnas-and-immunological-reactions
Press release - 18/12/2012 Phenex enters into a research collaboration and license agreement with Janssen Phenex Pharmaceuticals AG Phenex today announced it has entered into an agreement with Janssen Biotech Inc. and its affiliates Janssen to jointly discover compounds that target the nuclear hormone receptor RORT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis psoriasis and inflammatory bowel disease. https://www.gesundheitsindustrie-bw.de/en/article/press-release/phenex-enters-into-a-research-collaboration-and-license-agreement-with-janssen
Article - 15/10/2012 Vegetables help fend off bacteria in the intestines Their discovery in the human intestines came as quite a surprise up until a few years ago LTi lymphoid tissue inducer - cells were only known to be involved in the embryonic development of the immune system. A team of researchers led by Prof. Dr. Andreas Diefenbach from the University of Freiburg Medical Centre has since been able to show the protective role played by LTi cells in fortifying the intestinal wall as a reaction to nutrients found…https://www.gesundheitsindustrie-bw.de/en/article/news/vegetables-help-fend-off-bacteria-in-the-intestines
Article - 10/09/2012 Jan Wehkamp to investigate the causes of chronic inflammatory bowel diseases It takes a great deal of courage to question a common scientific doctrine especially for scientists at the very beginning of their careers. But around ten years ago Dr. Jan Wehkamp did not shy away from doing just that and as a result he and his scientific partner Professor Dr. Eduard Stange came up with a new explanation for the pathogenesis of chronic inflammatory bowel diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/jan-wehkamp-to-investigate-the-causes-of-chronic-inflammatory-bowel-diseases
Press release - 07/08/2012 immatics announces publication of IMA901 cancer vaccine data in Nature Medicine immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
Press release - 01/08/2012 With broccoli against infections The microbiologist and immunologist Prof. Dr. Andreas Diefenbach, Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Centre, has been awarded a European Research Council "Starting Grant" for his project "NutrImmune". The ERC Starting Grant is one of Europe’s most prestigious grants for young investigators.https://www.gesundheitsindustrie-bw.de/en/article/press-release/with-broccoli-against-infections
Article - 26/03/2012 More public attention for exotic diseases - Part 2 An international conference on rare diseases was held in Freiburg Germany in February 2012 where BIOPRO talked with Prof. Dr. Bodo Grimbacher director of the Centre of Chronic Immunodeficiency CCI in Freiburg and Prof. Dr. Maximilian Muenke paediatrician and human geneticist from the National Human Genome Research Institute NHGRI in the USA. Between them the two experts have a great deal of experience in rare diseases amongst other areas. Read in…https://www.gesundheitsindustrie-bw.de/en/article/news/more-public-attention-for-exotic-diseases-part-2
Article - 20/02/2012 Klaus Pfizenmaier: bridging the fields between immunology and biomedicine Prof. Dr. Klaus Pfizenmaier has been focusing on cytokines, and in particular on the tumour necrosis factor TNF, for the last 25 years. Pfizenmaier and his team of researchers at the Institute of Cell Biology and Immunology at the University of Stuttgart have unravelled numerous facets of TNF, which is a key and versatile signalling molecule. These discoveries have led to the development of groundbreaking therapy concepts and drug candidates for…https://www.gesundheitsindustrie-bw.de/en/article/news/klaus-pfizenmaier-bridging-the-fields-between-immunology-and-biomedicine
Article - 09/01/2012 Nutritional medicine: Can certain foods help treat cancer? Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.https://www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
Article - 19/12/2011 Gundram Jung – a pioneer in antibody-mediated cancer immunotherapy Physicist, medical doctor, researcher and now also a founder of a company – Professor Dr. Gundram Jung’s career has never gone in a completely straight line although his goal has always been the same: to develop innovative immunotherapies for the treatment of cancer. Jung’s genetically modified antitumour antibodies are now close to clinical application. https://www.gesundheitsindustrie-bw.de/en/article/news/gundram-jung-a-pioneer-in-antibody-mediated-cancer-immunotherapy
Dossier - 12/12/2011 Development of new molecular biomarkers Biomarkers are playing an increasing role in drug discovery and development. They can be used as molecular indicators for diseases and disease risks as well as for monitoring the effectiveness of therapy. Highly specific molecular biomarkers are being identified using state-of-the-art technologies from the fields of genomics, proteomics and metabolomics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/development-of-new-molecular-biomarkers
Press release - 30/11/2011 Researchers are challenging a common model of immunology Up to now, scientists have assumed that mast cells, a certain type of immune cells, play a central role in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Current studies conducted at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now provided evidence to refute this assumption. Now it is only the mast cells’ central function in allergies that remains undisputed.https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-are-challenging-a-common-model-of-immunology
Press release - 15/11/2011 Lung cancer: CureVac presents results of a Phase I/IIa trial with an mRNA based vaccine CureVac GmbH, the mRNA vaccine company, presented at the 26th Annual SITC Meeting in Washington the results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-cancer-curevac-presents-results-of-a-phase-i-iia-trial-with-an-mrna-based-vaccine
Article - 14/11/2011 Marina Freudenberg and Chris Galanos – more than 40 years of bacterial defence research This years Nobel Prize in Medicine or Physiology was awarded to three renowned scientists one of whom is the American Bruce Beutler who was instrumental in clarifying the structure of the mammalian Toll-like 4 TLR4 receptor. Prof. Dr. med. Marina Freudenberg and Dr. Dr. h.c. Chris Galanos from the Freiburg-based Max Planck Institute MPI of Immunobiology and Epigenetics have co-authored the key publication that led to the award of the Nobel Prize…https://www.gesundheitsindustrie-bw.de/en/article/news/marina-freudenberg-and-chris-galanos-more-than-40-years-of-bacterial-defence-research
Article - 17/10/2011 “The only way of keeping competition in the international market at bay” Biotech companies operate mostly on a global level. This is either because they follow their customers or because their major markets are abroad or because their domestic markets are so small that they are obliged to market their products abroad. Patents do not play a key role in all industries, but are of decisive strategic importance in the biotechnology sector. "However, patents are not always the best," says Ulrike Cremer, a patent…https://www.gesundheitsindustrie-bw.de/en/article/news/the-only-way-of-keeping-competition-in-the-international-market-at-bay
Article - 17/10/2011 Papillomaviruses as cancer-causing agents and how they can be fought off Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…https://www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off
Press release - 03/10/2011 Astonishing discovery: iron-overloading of macrophages is the cause of venous leg ulcers Around three to five per cent of people in industrial nations suffer from chronic venous leg ulcers. Elderly people are particularly prone to developing these chronic wounds. A dermatologist from Ulm has now discovered the reason why chronic venous leg ulcers fail to heal even after months or years. The scientific community is astonished by the new findings.https://www.gesundheitsindustrie-bw.de/en/article/press-release/astonishing-discovery-iron-overloading-of-macrophages-is-the-cause-of-venous-leg-ulcers
Article - 12/09/2011 TransLimm brings new immunotherapies to patients more rapidly With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology. https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
Article - 29/07/2011 Labor Dr. Merk und Kollegen - Viruses under control It is difficult to imagine how Ochsenhausen-based Labor Dr. Merk und Kollegen (LMK) would be able to develop, produce and test medical products for bacterial and viral contaminations without using cell cultures. The medium-sized company also produces viruses for testing and has stored more than 80 different viruses – enveloped and non-enveloped ones, animal and human pathogens – at -80˚C.https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-und-kollegen-viruses-under-control
Article - 27/06/2011 The EURAT project at the Marsilius Kolleg in Heidelberg Bioinformaticians, human geneticists, molecular biologists, oncologists, pathologists, lawyers and theologians are all participating in the project “Ethical and legal aspects of the total sequencing of the human genome” (EURAT) being carried out at Heidelberg University’s Marsilius Kolleg. The project partners are developing a common viewpoint and working out solutions for problems arising from the possibilities of total genome sequencing. https://www.gesundheitsindustrie-bw.de/en/article/news/the-eurat-project-at-the-marsilius-kolleg-in-heidelberg
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Dossier - 30/05/2011 Knowledge and technology transfer as a social responsibility Technology transfer that efficiently exploits the intellectual property created by publicly funded research is necessary in order to turn scientific discoveries into successful innovations that improve people’s quality of life and boost the economy. The efforts made to rapidly transfer research results from the laboratory into clinical application for the benefit of patients leads to new strategic partnerships and structures in the field of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/knowledge-and-technology-transfer-as-a-social-responsibility